Recreational Ketamine-Induced Uropathy: Recognition and Management in Care

[smfadmin (OP)]

https://www.psychiatrist.com/pcc/recreational-ketamine-induced-uropathy/?utm_source=Klaviyo&utm_medium=email&utm_campaign=news_wmr&klid=01HYSTTNXNB74YAYKT9XMYQCN0&_kx=va3uRF3O8-7Dg_zjrKMZJk0wdery-TOTVyZ3l8muM1g.VpkqxC

March 19, 2026

Ketamine is a phencyclidine derivative with N-methyl-D-aspartate receptor antagonist properties used for decades as an anesthetic and analgesic. At subanesthetic doses, it produces dissociative and psychotropic effects, prompting inquiry into its utility for psychiatric conditions. Racemic ketamine, a mixture of equal parts R- and S-enantiomers, has been studied off-label for treatment-resistant depression and other psychiatric disorders.1 More recently, intranasal S-ketamine (esketamine) received US Food and Drug Administration approval for treatment-resistant depression.

Outside of clinical settings, ketamine has a long history of nonmedical use. Early surveys in the 1990s documented recreational use in clubs, concerts, and “rave” environments, driven by its dissociative and hallucinogenic properties. In the United States, population-based survey data indicate that recreational ketamine use, while still uncommon, has increased over the past decade. Analyses from the National Survey on Drug Use and Health show that past-year ketamine use among adults increased by 81% from 0.11% in 2015 to 0.20% in 2019 and subsequently increased by 40% from 0.20% in 2021 to 0.28% in 2022, suggesting growing population-level exposure.2 Adults reporting past-year ketamine use were initially concentrated in younger age groups, but more recent increases have been observed among adults aged 26–34 years, indicating a broadening demographic of recreational users.2,3 Complementing these survey findings, drug seizure records demonstrate a substantial increase in illicit ketamine availability in the United States between 2017 and 2022.4

Illicit ketamine is obtained through several channels. Historically, supplies have come from veterinary diversion, international trafficking, or local synthesis. Some users acquire ketamine through dark web marketplaces, purchased with cryptocurrency to maintain anonymity.5 More recently, concerns have arisen about telehealth prescribing platforms that provide ketamine with little or no formal evaluation for off-label psychiatric indications,6 with some patients escalating doses or diverting medication for nonmedical use. This evolving access underscores the overlap between therapeutic exposure and recreational misuse.

Recreational ketamine can be acquired in liquid or powder forms. Powdered ketamine is commonly insufflated. Liquid ketamine is injected intravenously or intramuscularly or, less commonly, ingested orally or used rectally.7,8 Orally ingested ketamine is rapidly metabolized to norketamine, producing more of a sedative and less of a psychedelic experience.7 Compared with oral use, intranasal or parenteral administration provides faster onset and greater intensity of dissociative effects. Street formulations vary in purity, and slang terms such as “Special K,” “Vitamin K,” or “Kit-Kat” reflect its reputation in recreational drug culture.

The reinforcing appeal of ketamine lies in its rapid onset of euphoria, increased sociability, dissociation, and altered perception of time and space.7,8 Its relatively short duration of action, low cost, and accessibility make it attractive to those seeking intense psychoactive experiences.9 Tolerance develops quickly, necessitating escalating doses to achieve similar effects,9 increasing the risks of psychiatric and physical complications.

Chronic, heavy use has been strongly linked to ketamine-induced uropathy (KIU),10,11 which typically presents with cystitis-like lower urinary tract symptoms (LUTS).12,13 KIU can progress to severe bladder and upper urinary tract injury if use continues.14,15

Despite increasing recognition in urologic literature, KIU remains underrecognized in psychiatric and primary care settings, leading to extensive evaluation for infection or interstitial cystitis, repeated empirical antibiotic treatment despite negative urine cultures, and disease progression.16,17 Without awareness of ketamine exposure, the underlying etiology may go undetected, delaying appropriate treatment and drug cessation. For primary care physicians, psychiatrists, and other mental health providers, consideration of recreational ketamine use is therefore essential when patients present with unexplained urinary complaints.

Here, we present 2 cases that illustrate the psychiatric and urologic consequences of KIU. These reports highlight the diagnostic challenges posed by KIU, the role of psychiatric comorbidity in ongoing use, and the need for multidisciplinary management.

Go to the link full the case studies.